Floatz logo

Conestat Alfa

Acute Renal Injury

University Hospital, Basel, Switzerlandprotein_peptidePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Acute Renal Injury cohort.

Asset / SponsorPhaseRating
Giapreza
The Cleveland Clinic
Phase 4BB
Everolimus
MARIO ABBUD FILHO
Phase 4B
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
Tanta University
Phase 4B
PROPRANOLOL
Taipei Veterans General Hospital, Taiwan
Phase 4B
NORMAL HUMAN SERUM ALBUMIN
Institute of Liver and Biliary Sciences, India
Phase 3B

View all 32 →

Same molecule, other indications

Conestat Alfa is also rated in:

hereditary angioedemaDormant
BBB
Indicative ·
74 / 100
View asset →
common variable immunodeficiencyDormant
BB
Indicative ·
66 / 100
View asset →
injuryDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →